{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:23:10Z","timestamp":1788351790583,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2023-00216446"],"award-info":[{"award-number":["RS-2023-00216446"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.05.013","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:19:34Z","timestamp":1782109174000},"page":"1571-1579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65 to 69 Years (CAREMM-2110 Study)"],"prefix":"10.1016","volume":"29","author":[{"given":"Jung Yeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungpil","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonggyu","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suein","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jval.2026.05.013_bib1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jval.2026.05.013_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jval.2026.05.013_bib3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4143\/crt.2025.264","article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2022","volume":"57","author":"Park","year":"2025","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s44313-025-00069-3","article-title":"Real-world treatment patterns, outcomes, and economic costs by lines of therapy in patients with newly diagnosed multiple myeloma: a nationwide population-based cohort study in South Korea","volume":"60","author":"Park","year":"2025","journal-title":"Blood Res"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.05.013_bib5","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.5045\/br.2020.S007","article-title":"Frontline therapy for newly diagnosed patients with multiple myeloma","volume":"55","author":"Jung","year":"2020","journal-title":"Blood Res"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.jval.2026.05.013_bib7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.jval.2026.05.013_bib8","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.jval.2026.05.013_bib9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Terpos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.jval.2026.05.013_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2025.10.021","article-title":"A large-scale analysis of autologous stem cell transplantation for multiple myeloma patients older than 65 years","volume":"26","author":"S\u00e1ez-Mar\u00edn","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib11","first-page":"286","article-title":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients","volume":"111","author":"Mizuno","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.jval.2026.05.013_bib12","article-title":"Retrospective claims data analysis of ASCT characteristics and costs for working-age multiple myeloma patients in the US, 2017-2019","volume":"23","author":"Chi","year":"2025","journal-title":"Leuk Res Rep"},{"issue":"12","key":"10.1016\/j.jval.2026.05.013_bib13","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.ebiom.2015.11.021","article-title":"Economics and outcome after hematopoietic stem cell transplantation: a retrospective cohort study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"EBiomedicine"},{"issue":"10","key":"10.1016\/j.jval.2026.05.013_bib14","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bbmt.2015.05.013","article-title":"Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the Surveillance, Epidemiology, and End Results\u2013Medicare database","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jval.2026.05.013_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075047","article-title":"Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis","volume":"8","author":"Corso","year":"2013","journal-title":"PLOS One"},{"issue":"10","key":"10.1016\/j.jval.2026.05.013_bib16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/ctr.12421","article-title":"Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma","volume":"28","author":"Pandya","year":"2014","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jval.2026.05.013_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105507","article-title":"Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing-remitting multiple sclerosis","volume":"84","author":"Gottschlich","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.jval.2026.05.013_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s41669-024-00554-y","article-title":"Economic burden of acute myeloid leukemia in the European Union: results from a systematic review of literature","volume":"9","author":"Saeed","year":"2025","journal-title":"Pharmacoecon Open"},{"issue":"2","key":"10.1016\/j.jval.2026.05.013_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s41669-022-00374-y","article-title":"Estimating the incidence-based cost of illness due to hematopoietic stem cell transplantation using one-year insurance claim data in Korea","volume":"7","author":"Kwon","year":"2023","journal-title":"Pharmacoecon Open"},{"issue":"2","key":"10.1016\/j.jval.2026.05.013_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/19371910903070333","article-title":"Introduction: health of the health care system in Korea","volume":"25","author":"Kim","year":"2010","journal-title":"Soc Work Public Health"},{"issue":"3","key":"10.1016\/j.jval.2026.05.013_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4078\/jrd.2021.28.3.119","article-title":"Clinical study using healthcare claims database","volume":"28","author":"Park","year":"2021","journal-title":"J Rheum Dis"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41698-023-00385-w","article-title":"ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma","volume":"7","author":"Park","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib23","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1038\/s41598-024-52720-1","article-title":"Quantitative risk factor analysis of prior disease condition and socioeconomic status with the multiple myeloma development: nationwide cohort study","volume":"14","author":"Choi","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.jval.2026.05.013_bib24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s40273-019-00828-y","article-title":"Cost effectiveness of transplant, conventional chemotherapy, and novel agents in multiple myeloma: a systematic review","volume":"37","author":"Fu","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.05.013_bib25","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.5045\/br.2020.S008","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"55","author":"Lee","year":"2020","journal-title":"Blood Res"},{"issue":"5","key":"10.1016\/j.jval.2026.05.013_bib26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4093\/dmj.2014.38.5.395","article-title":"Background and data configuration process of a nationwide population-based study using the Korean National Health Insurance system","volume":"38","author":"Song","year":"2014","journal-title":"Diabetes Metab J"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4143\/crt.2025.046","article-title":"Cost-effectiveness assessment of treatment sequences for multiple myeloma using nationwide claims data in Korea","volume":"58","author":"Park","year":"2026","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10238-024-01368-2","article-title":"Major cardiovascular events in long-term multiple myeloma survivors: a Korean case-control study (CAREMM-2105)","volume":"24","author":"Ha","year":"2024","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.jval.2026.05.013_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/fon-2020-1003","article-title":"Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA","volume":"17","author":"Madduri","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","article-title":"Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States","volume":"32","author":"Song","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2026.05.013_bib31","first-page":"136","article-title":"The Charlson comorbidity Index: problems with use in epidemiological research","volume":"147","author":"Drosdowsky","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jval.2026.05.013_bib32","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hec.3871","article-title":"Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data","volume":"28","author":"Hatswell","year":"2019","journal-title":"Health Econ"},{"issue":"8","key":"10.1016\/j.jval.2026.05.013_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbmt.2018.03.027","article-title":"Health-related quality of life after autologous stem cell transplantation for multiple myeloma","volume":"24","author":"Chakraborty","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jval.2026.05.013_bib34","series-title":"Bortezomib and thalidomide for the first-line treatment of multiple myeloma. Nice Technology Appraisal Guidance TA228","year":"2011"},{"key":"10.1016\/j.jval.2026.05.013_bib35","series-title":"Guidelines for Economic Evaluation of Pharmaceuticals","year":"2021"},{"key":"10.1016\/j.jval.2026.05.013_bib36","article-title":"Evaluation of willingness to pay per quality-adjusted life year for a cure: a contingent valuation method using a scenario-based survey","volume":"96","author":"Song","year":"2017","journal-title":"Med (Baltim)"},{"issue":"4","key":"10.1016\/j.jval.2026.05.013_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266934","article-title":"Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review","volume":"17","author":"Iino","year":"2022","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial","volume":"107","author":"Pawlyn","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jval.2026.05.013_bib39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajh.25797","article-title":"Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the International Myeloma Working Group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years","volume":"95","author":"Belotti","year":"2020","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.jval.2026.05.013_bib40","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jval.2026.05.013_bib41","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jval.2026.05.013_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m2 or 200 mg\/m2 for autologous transplantation in myeloma: results from the CALM study","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jval.2026.05.013_bib43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/CEOR.S152437","article-title":"Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia","volume":"10","author":"Qerimi","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12885-025-13615-0","article-title":"Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study","volume":"25","author":"Yoon","year":"2025","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jval.2026.05.013_bib45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/jha2.798","article-title":"Real-world utilization and healthcare costs for multiple myeloma: a retrospective analysis of patients in Singapore","volume":"4","author":"Bayani","year":"2023","journal-title":"Ejhaem"},{"issue":"4","key":"10.1016\/j.jval.2026.05.013_bib46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/ejh.13922","article-title":"Tandem autologous stem cell transplantation in elderly patients with myeloma: a multicenter retrospective analysis","volume":"110","author":"Suzuki","year":"2023","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12955-025-02419-2","article-title":"Health-related quality of life and financial toxicity in Chinese patients with multiple myeloma: a two-year real-world multicentre study","volume":"23","author":"Wu","year":"2025","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.jval.2026.05.013_bib48","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.2021015220","article-title":"Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma","volume":"140","author":"Yamamoto","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jval.2026.05.013_bib49","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.20.01849","article-title":"Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma","volume":"39","author":"Patel","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.05.013_bib50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible newly diagnosed multiple myeloma: results from the MajesTEC-5 trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.jval.2026.05.013_bib51","article-title":"Phase 3 randomized study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab-based therapy in relapsed\/refractory multiple myeloma: MajesTEC-3 trial","volume":"146","author":"Mateos","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jval.2026.05.013_bib52","article-title":"Cost-effectiveness of anti-BCMA chimeric antigen receptor T cell therapy in relapsed\/refractory multiple myeloma","volume":"30","author":"Yamamoto","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"10.1016\/j.jval.2026.05.013_bib53","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:06:21Z","timestamp":1788350781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1098301526025015"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.05.013","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65 to 69 Years (CAREMM-2110 Study)","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}